Ascendis Pharma shares climbed 3.0% in the most recent trading session, driven by an above-average volume of 5.8 million shares, compared with the three-month daily average of 3.2 million. This 82% increase in turnover suggests heightened investor engagement following the company’s December 14 announcement that topline data from the late-stage YORVIPATH trial demonstrated a statistically significant 18% improvement in patient adherence over daily injections. Despite the rally, the stock remains 12% below its year-to-date high, indicating that some investors may be taking profits after a 35% gain since the beginning of the year.

Over the past four weeks, analysts have lowered their 2024 EPS forecasts for ASND by an average of $0.02, bringing the consensus estimate to a loss of $0.45 per share. At the same time, the average revenue estimate for 2024 has been trimmed by $15 million to $275 million, reflecting slower-than-expected uptake of SKYTROFA in the U.S. pediatric growth hormone market. Only two out of ten research firms have issued upward revisions during this period, suggesting limited near-term upside in institutional projections.

During Ascendis Pharma’s presentation at the 44th Annual JPMorgan Healthcare Conference on January 9, CEO Jan Mikkelsen outlined a regulatory submission timeline for YORVIPATH with the European Medicines Agency, targeting a filing in 3Q24. CFO Scott Smith emphasized ongoing discussions with potential strategic partners in Asia and reaffirmed guidance for R&D spending of $380 million in 2024, a 22% increase over the prior year. The firm also disclosed plans to initiate a Phase II trial of TransCon PTH in hypoparathyroidism patients by mid-2024.